Peripheral blood stem cells for treatment of hematologic malignancies

The purpose of this clinical application is to demonstrate the use of peripheral blood stem cells, extracted from related, haploidentical donors, as the source of lymphocytes and stem cells for nonmyeloablative transplants, in place of using marrow as a source. This approach is projected to avoid unsatisfactory rates of high-grade acute or chronic GvHD, nonrelapse mortality (NRM) or relapse, when compared to the literature on nonmyeloablative transplants from unrelated donors.